BIDMC researchers find that 137 million adults are eligible for semagludtide for weight loss, diabetes management or recurrent cardiovascular event prevention.
A five-year residency program with world-class training in general urology, endourology/stone disease, neuro-urology, urologic oncology, reconstruction and pediatric urology Training residents has ...